June 2025 marked a month of significant progress in cancer care, as the FDA approved several new therapies and treatment combinations across a range of cancer types. As reported by…
The 2023 World Conference on Lung Cancer took place from September 9-12 this year. During the conference, stakeholders came together to discuss novel research, emerging trends, and other needs…
Over 50% of non-small cell lung cancer patients (NSCLC) will experience a recurrence after surgery. The cancer recurs even after adjuvant chemotherapy after major surgery. ALINA’s data show that Alecensa…
Currently, almost half the patients with non-small cell lung cancer (NSCLC) will see their disease return despite aggressive chemotherapy treatment (adjuvant surgery). Adjuvant therapy is treatment that is given…
Two years ago, China approved ensartinib as a second-line therapy for those with ALK+ non-small cell lung cancer (NSCLC). There have been advances over time. Now, according to a late…
Dr. Joshua Sabari, a professor at New York University's Department of Medicine, has recently spoken about the different treatment options for ALK-positive non-small cell lung cancer (NSCLC). Specifically, he discussed…
According to a recent article from Medscape, Takeda Pharmaceuticals is offering a rebate for brigatinib (Alunbrig) which is used for the treatment of non-small cell lung cancer. Non-Small Cell Lung…
FoundationOne CDx is a comprehensive genomic profiling test that is tissue based. It is used to identify individuals diagnosed with ALK+ non-small-cell lung cancer (NSCLC) who will be eligible for…
In some cases, combining different therapies can provide better overall outcomes for patients. However, in a Phase 2 clinical trial evaluating bevacizumab in conjunction with osimertinib for patients with EGFR-mutated…
Recently, Daiichi Sankyo and AstraZeneca announced a clinical trial collaboration to determine whether using a combination of TAGRISSO (osimertinib) and patritumab deruxtecan (U3-1402) would be effective in treating patients…
Roche has recently been granted priority review by the FDA, who has also accepted their supplemental biologics license application for atezolizumab. Atezolizumab is intended for the treatment of non-small cell…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
